首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >The use of scaffold-free cell sheet technique to refine mesenchymal stromal cell-based therapy for heart failure.
【24h】

The use of scaffold-free cell sheet technique to refine mesenchymal stromal cell-based therapy for heart failure.

机译:使用无支腿细胞板技术的使用来细化间充质基质细胞的心力衰竭治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Transplantation of bone marrow-derived mesenchymal stromal cells (MSCs) is an emerging treatment for heart failure based on their secretion-mediated "paracrine effects". Feasibility of the scaffoldless cell sheet technique to enhance the outcome of cell transplantation has been reported using other cell types, though the mechanism underpinning the enhancement remains uncertain. We here investigated the role of this innovative technique to amplify the effects of MSC transplantation with a focus on the underlying factors. After coronary artery ligation in rats, syngeneic MSCs were grafted by either epicardial placement of MSC sheets generated using temperature-responsive dishes or intramyocardial (IM) injection. Markedly increased initial retention boosted the presence of donor MSCs persistently after MSC sheet placement although the donor survival was not improved. Most of the MSCs grafted by the cell sheet technique remained resided on the epicardial surface, but the epicardium quickly regressed and new vessels sprouted into the sheets, assuring the permeation of paracrine mediators from MSCs into the host myocardium. In fact, there was augmented upregulation of various paracrine effect-related genes and signaling pathways in the early phase after MSC sheet therapy. Correspondingly, more extensive paracrine effects and resultant cardiac function recovery were achieved by MSC sheet therapy. Further development of this approach towards clinical application is encouraged.
机译:骨髓衍生的间充质基质细胞(MSCs)的移植是基于其分泌介导的“旁静脉效应”的心力衰竭的新出现治疗。使用其他细胞类型报告了脚腰细胞板技术的可行性,以提高细胞移植的结果,尽管支撑增强的机制仍然不确定。我们在这里调查了这种创新技术的作用,以扩大MSC移植的影响,重点关注潜在因素。在大鼠冠状动脉结扎后,通过使用温度响应菜肴或Intramyeachial(IM)注射产生的MSC片外膜胶片移植同联的MSC。显着增加的初始保留虽然供体存活率没有改善,但在MSC片材放置后持续增加供体MSCs的存在。由细胞片技术接种的大多数MSCs仍然留在心外膜表面上,但外膜速度迅速回归并散发到纸张中的新血管,并确保从MSCS到宿主心肌中的帕拉卡碱介质的渗透。实际上,在MSC片疗法后,在早期期间增加了各种旁静脉效应相关基因和信号通路的增强。通过MSC片疗法实现了相应地,更广泛的旁静脉效应和结果心功能恢复。鼓励进一步发展这种临床申请的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号